PMID- 19020736
OWN - NLM
STAT- MEDLINE
DCOM- 20090204
LR  - 20081121
IS  - 1021-335X (Print)
IS  - 1021-335X (Linking)
VI  - 20
IP  - 6
DP  - 2008 Dec
TI  - Comparison between intravenous and oral postoperative adjuvant immunochemotherapy 
      in patients with stage III colorectal cancer.
PG  - 1521-6
AB  - This study aimed to retrospectively assess the efficacy of postoperative adjuvant 
      chemotherapy in 77 patients who underwent curative resection for stage III 
      colorectal cancer. They were treated by intravenous administration of 5FU + LV 
      (FL-IV group, 38) or oral administration of UFT + PSK (oral group, 39). The 
      3-year relapse-free (3Y-RFS), 5-year relapse-free (5Y-RFS) and 5-year overall 
      survival (5Y-OS) were calculated for each group, and clinical results and adverse 
      events (AEs) were compared between the two groups. The 3Y-RFS, 5Y-RFS and 5Y-OS 
      were 65.8, 62.7 and 72.3%, respectively, in the FL-IV group and 63.3 (p=0.7957), 
      56.3 (p=0.7088) and 60.4% (p=0.5293), respectively, in the oral group. These 
      parameters showed no significant differences between the two groups. As AEs, 
      grade 3 leucopenia, nausea/vomiting, and general fatigue were noted in one 
      patient each (2.6%) in the FL-IV group. Grade 3 or more severe AEs were not noted 
      in the oral group. These results suggest that oral immunochemotherapy is one of 
      the options of postoperative adjuvant therapy for stage III colorectal cancer, 
      because it imposes no financial burden on patients and results in high quality of 
      life.
FAU - Ito, Isao
AU  - Ito I
AD  - Tokai University Oiso Hospital, Department of Surgery, Kanagawa 259-0198, Japan. 
      isaoito@is.icc.u-tokai.ac.jp
FAU - Mukai, Masaya
AU  - Mukai M
FAU - Ninomiya, Hiromi
AU  - Ninomiya H
FAU - Kishima, Kyoko
AU  - Kishima K
FAU - Tsuchiya, Kazutoshi
AU  - Tsuchiya K
FAU - Tajima, Takayuki
AU  - Tajima T
FAU - Nakamura, Masato
AU  - Nakamura M
FAU - Makuuchi, Hiroyasu
AU  - Makuuchi H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Administration, Oral
MH  - Antineoplastic Agents/administration & dosage
MH  - Chemotherapy, Adjuvant/methods
MH  - Colorectal Neoplasms/*immunology/*surgery/*therapy
MH  - Combined Modality Therapy/methods
MH  - Disease-Free Survival
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Infusions, Intravenous
MH  - Japan
MH  - Models, Statistical
MH  - Neoplasm Metastasis
MH  - Recurrence
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2008/11/21 09:00
MHDA- 2009/02/05 09:00
CRDT- 2008/11/21 09:00
PHST- 2008/11/21 09:00 [pubmed]
PHST- 2009/02/05 09:00 [medline]
PHST- 2008/11/21 09:00 [entrez]
PST - ppublish
SO  - Oncol Rep. 2008 Dec;20(6):1521-6.